生物疗法和牛皮的主要心血管事件:更新的系统审查和元分析
Varitsara Mangkorntongsakul1, J S Joseph2, James P Pham3,4
1Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Dermatology and therapy
|October 28, 2025
概括
严重斑块性牛皮的生物疗法不会增加主要心血管不良事件 (MACE) 的风险. 这次系统性审查发现,在牛皮患者中,生物药物和安慰剂之间的MACE风险没有显著差异.
科学领域:
- 皮肤病学和免疫学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 牛皮经常与心血管疾病有关.
- 生物疗法对于严重的斑块性牛皮是有效的,但其心血管安全性尚未完全理解.
研究的目的:
- 研究生物疗法对慢性斑块牛皮患者重大心血管不良事件 (MACE) 风险的影响.
主要方法:
- 随机对照试验 (RCT) 的系统审查和元分析,公布时间为2022年5月10日.
- 包含的RCT比较了成年中度至重度斑块性牛皮的许可生物疗法与安慰剂或其他生物药物.
- 遵守系统审查和元分析 (PRISMA) 准则的首选报告项目.
主要成果:
- 对43个RCT的分析发现,生物疗法和安慰剂之间的MACE风险没有统计学上显著的差异 (Peto概率比率[POR]1.26,95%CI0.53至3.01,P=0.59).
- 特定的生物类,包括TNF-alpha,IL-17,IL-12/23和IL-23抑制剂,没有显示与MACE风险增加的显著关联.
结论:
- 抗牛皮生物疗法与牛皮患者的MACE风险增加无关.
- 需要进行长期研究和营销后监测,以充分阐明这些治疗方法的心血管安全性.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
478
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
478
Psychoneuroimmunology: Cardiovascular Disease
382
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
A key area of focus in PNI is the relationship between stress and coronary...
382
Cardiovascular Drugs: Classification based on Therapeutic Indications
4.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.0K
Atherosclerosis III: Management
312
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
312
Rheumatic Heart Disease III: Medical Management
278
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
278
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
473
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
473

